论文部分内容阅读
目的：探讨选择性支气管动脉灌注化疗（ＢＡＩ）对中晚期肺癌的疗效及影响因素。方法：对６９例中晚期肺癌进行ＢＡＩ治疗，根据不同病期、组织类型、病变部位、肿瘤血管构型、血供类型及操作技术进行分析。结果：（１）中央型，小细胞未分化癌及鳞癌、多血管构型、少血供者与周围型、腺癌、少血管构型、多血供患者之间疗效差异有显著性，前者优于后者（Ｐ＜０．０５）。（２）６９例中ＢＡＩ后肺内局部病变完全缓解（ＣＲ）１５例（２１７％），部分缓解（ＰＲ）３２例（４６４％），缓解（ＣＲ＋ＰＲ）４７例，缓解率６８１％。其中小细胞未分化癌、鳞癌、腺癌的缓解率分别为９３２％、７９４％、５１５％。结论：（１）Ⅳ期病人不适合ＢＡＩ治疗。（２）鳞癌首选ＢＡＩ治疗，小细胞未分化癌以全身化疗为基础，辅助应用ＢＡＩ治疗，腺癌可先行ＢＡＩ治疗，几次ＢＡＩ治疗中间或之后，配合全身化疗或放疗，治疗或消灭远处转移。
Objective: To investigate the efficacy and influencing factors of selective bronchial arterial infusion chemotherapy (BAI) for advanced lung cancer. METHODS: BAI treatment was performed on 69 patients with advanced lung cancer. The analysis was performed according to different stages, tissue types, lesion locations, tumor vessel configuration, blood supply type, and operation techniques. Results: (1) There was significant difference in efficacy between central undifferentiated and small cell undifferentiated carcinomas and squamous cell carcinoma, multi-vessel configuration, hypovascular donors and peripheral type, adenocarcinomas, small vessel configuration, and multiple blood supply. The former was better than the latter (P<0.05). (2) In 69 cases, 15 cases (21.7%) of complete remission of lung lesions after BAI, 32 cases (46.4%) of partial remission (PR), 47 cases of remission (CR+PR), and 68 cases of remission. 1%. Among them, the remission rates of small cell undifferentiated carcinoma, squamous cell carcinoma and adenocarcinoma were 932%, 794%, and 515%, respectively. Conclusions: (1) Patients with stage IV are not eligible for BAI treatment. (2) The squamous cell carcinoma is the first choice for BAI treatment, and the small cell undifferentiated carcinoma is based on systemic chemotherapy. It is supplemented with BAI treatment. Adenocarcinoma can be treated with BAI first, and several times after BAI treatment is used together with systemic chemotherapy or radiotherapy to treat or eradicate the disease. Transfer.